title: Community-based phase II trial of PCR for CLL/SLL patients.
authors.forename: Neil E
authors.initials: NE
authors.lastname: Kay
authors.forename: Tait D
authors.initials: TD
authors.lastname: Shanafelt
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
authors.forename: Michael R
authors.initials: MR
authors.lastname: Grever
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology; D015649:Pentostatin / Q000009:adverse effects / Q000627:therapeutic use*; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D015649:Pentostatin; D000069283:Rituximab; D003520:Cyclophosphamide